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Abstract There may be a relationship between the inci-
dence of vasomotor and arthralgia/myalgia symptoms and
treatment outcomes for postmenopausal breast cancer
patients with endocrine-responsive disease who received
adjuvant letrozole or tamoxifen. Data on patients random-
ized into the monotherapy arms of the BIG 1-98 clinical trial
who did not have either vasomotor or arthralgia/myalgia/
carpal tunnel (AMC) symptoms reported at baseline, started
protocol treatment and were alive and disease-free at the
3-month landmark (n = 4,798) and at the 12-month land-
mark (n = 4,682) were used for this report. Cohorts of
patients with vasomotor symptoms, AMC symptoms, nei-
ther, or both were defined at both 3 and 12 months from
randomization. Landmark analyses were performed for
disease-free survival (DFS) and for breast cancer free
interval (BCFI), using regression analysis to estimate hazard
ratios (HR) and 95 % confidence intervals (CI). Median
follow-up was 7.0 years. Reporting of AMC symptoms was
associated with better outcome for both the 3- and 12-month
landmark analyses [e.g., 12-month landmark, HR (95 % CI)
for DFS = 0.65 (0.49–0.87), and for BCFI = 0.70
(0.49–0.99)]. By contrast, reporting of vasomotor symptoms
was less clearly associated with DFS [12-month DFS HR
(95 % CI) = 0.82 (0.70–0.96)] and BCFI (12-month DFS
HR (95 % CI) = 0.97 (0.80–1.18). Interaction tests indi-
cated no effect of treatment group on associations between
symptoms and outcomes. While reporting of AMC symp-
toms was clearly associated with better DFS and BCFI, the
association between vasomotor symptoms and outcome was
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less clear, especially with respect to breast cancer-related
events.
Keywords Aromatase inhibitor  Side effects  Breast
cancer  Endocrine therapy
Background
Adjuvant treatments that suppress or block estrogens are
effective for hormone-sensitive breast cancer, resulting in
better relapse free and overall survival [1]. For several
decades, the standard treatment has been tamoxifen. Recent
studies have shown that the use of aromatase inhibitors
(AIs) is associated with a better outcome compared to
tamoxifen in postmenopausal breast cancer patients [2–4].
Tamoxifen blocks the estrogen receptor, while AIs sup-
press estrogen levels by inhibiting the enzyme responsible
for conversion of androgens to estrogens in the peripheral
tissue. The CYP19A1 gene encodes the aromatase enzyme,
and polymorphisms in this gene may impact estrogen
levels [5, 6]. Tamoxifen is converted in vivo mainly by the
cytochrome p450 enzyme CYP2D6 to endoxifen in order to
exert adequate receptor blockade [7]. This metabolic
capacity is genetically determined and can additionally be
influenced by concomitant medication [8, 9].
Adverse events of AIs and tamoxifen differ significantly
in incidence, most likely as a result of their specific
mechanism of action. Adverse events more commonly seen
with AIs include arthralgia, musculoskeletal disorders,
osteoporosis, vaginal dryness, and dyspareunia. Adverse
events more frequently observed with tamoxifen include
thromboembolic events, endometrial disorders, and hot
flushes [10]. Although many of these adverse events do not
threaten the safety of the patient, short and long term
inconvenience may lead to treatment discontinuation [11].
However, not every patient develops treatment-emergent
endocrine side effects, and the appearance of these adverse
events may reflect the degree of estrogen blockade or
estrogen suppression in the individual patient, as well as
characterizing the host hormonal environment. Thus, the
occurrence of side effects frequently associated with
endocrine therapies, along with other known factors, may
help predict the efficacy of hormonal therapy.
For some drugs, there is evidence that the occurrence of
specific side effects may predict the likelihood of treatment
success. In HER1/EGFR-targeted agents, treatment efficacy
was linked to the occurrence of acneiform skin rash [12]. In
some trials, the appearance of hypertension was an indicator
of response to treatment with the angiogenesis inhibitor
bevacizumab [13]. Currently available evidence of the
association of endocrine-related side effects and efficacy in
patients who received hormonal treatment is, however,
conflicting and inconclusive.
In this retrospective analysis of prospectively-collected
data of adverse events, we evaluated disease-related out-
comes of patients from the BIG 1-98 trial treated with
5 years of letrozole or tamoxifen according to the inci-
dence of vasomotor and arthralgia/myalgia/carpal tunnel
(AMC) symptoms reported within 3 and 12 months fol-
lowing randomization.
Patients and methods
Study design
The BIG 1-98 trial [2] is an international randomized
multicenter double-blind phase 3 trial that enrolled 8,010
postmenopausal patients with hormone receptor-positive
early breast cancer. Patients were randomized to mono-
therapy with 5 years tamoxifen (20 mg daily p.o), or
5 years letrozole (Femara, Novartis, Basel, Switzerland,
2.5 mg daily p.o), or to sequential treatment with tamoxi-
fen for 2 years followed by 3 years of letrozole or the
reverse. The monotherapy arms, used in this analysis,
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included 4,922 patients. At a median follow-up of
8.7 years, letrozole monotherapy was associated with a
significantly better DFS, breast cancer free interval (BCFI),
and OS than tamoxifen monotherapy [2].
Assessments
Medical histories and physical examinations were done at
baseline, twice per year for the first 5 years and yearly
thereafter. Hematological and blood chemical measure-
ments and mammograms were obtained at baseline and
additionally when medically indicated. Data on adverse
events were obtained using pre-specified check-boxes for
vasomotor symptoms and text field responses for AMC
symptoms. Date of onset and severity of these adverse
events were recorded and rated by the investigators using
the National Cancer Institute Common Toxicity Criteria,
version 2.0. For this analysis, only patients with at least one
dose of study medication without a DFS event during the
first 3 months or any known vasomotor or AMC symptoms
prior to the start of study treatment were evaluated (Fig. 1).
Vasomotor symptoms included hot flushes, night sweats,
and vaginal dryness of any grade; AMC symptoms inclu-
ded arthralgia, myalgia, and carpal tunnel syndrome of any
grade. Endpoints were DFS and BCFI for newly-occurring
symptoms at the 3 and 12 month time points. In addition,
we analyzed the incidence of endocrine side effects for
tamoxifen and letrozole at 3 and 12 months follow-up.
A DFS event was defined as the occurrence of any invasive
breast cancer event, second malignancy, and death. A BCFI
event was defined as any invasive breast cancer event, with
all other events (e.g., other-cause death, second malig-
nancy) treated as competing risks.
Statistical analysis
Adverse event data were used to determine the occurrence of
AMC symptoms and vasomotor symptoms within 3 and
12 months of randomization using date of onset, as the basis
for landmark analysis at these two time points [14]. Adverse
event occurrence was categorized as follows: AMC symp-
toms only, vasomotor symptoms only, neither symptom, and
both symptoms. In addition, the analysis considered the
occurrence of AMC symptoms with or without vasomotor
symptoms, vasomotor symptoms with or without AMC
symptoms, either symptom alone (AMC or vasomotor
symptoms but not both) and both symptoms. Adverse event
rates were compared using Fisher’s exact test [15]. Logistic
regression was used to assess the association between
baseline characteristics and incidence of AMC and/or
vasomotor symptoms. The percent of patients discontinuing
study treatment within 4.5 years for reasons other than dis-
ease recurrence was estimated using competing risk analysis.
Analyses of DFS and BCFI were performed using
standard methods for time-to-event data. DFS was ana-
lyzed using the Kaplan–Meier product limit method [16],
with comparisons based on the log-rank test [17]. BCFI
was analyzed using methods for competing risks. The
cumulative incidence of BCFI was compared using the
method of Gray [18].
The 3-month analysis excluded patients who experienced
disease recurrence, new cancer, or death during the first
3 months following randomization. DFS and BCFI were
then analyzed by evaluating outcomes from the 3-month
time point forward. The 12-month analysis was similarly
performed after excluding patients who experienced disease
recurrence, new cancer, or death during the first 12 months
following randomization.
Enrolled in BIG 1-98
N =8010
Enrolled in monotherapy 
treatments N =4922
Enrolled in sequential treatments
N=3088
Tamoxifen
N =2459
Letrozole 
N =2463
Tamoxifen
N =2402
Letrozole
N =2396
Tamoxifen
N=2344
Letrozole 
N=2338
Excluded 57 patients
• 12 did not receive trial treatment
• 28 had baseline symptoms
• 4 missing nodal status
• 13 had DFS event within 3 months
Excluded additional 58 patients 
with DFS event within 12 mos. 
Excluded additional 58 patients 
with DFS event within 12 mos. 
Included in 3-month analysis
N =4798
Included in 12-month analysis
N =4682
Excluded 67 patients
• 15 did not receive trial treatment
• 41 had baseline symptoms
• 1 missing nodal status
• 10 had DFS event within 3 months
Fig. 1 Consort diagram showing the patient population for this analysis
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Table 1 Baseline characteristics
Letrozole (N = 2,396) Tamoxifen (N = 2,402) Total (N = 4,798)
number (%)
Menopausal category
Postmenopausal before chemotherapy, if received 2,321 (97) 2,313 (97) 4,634 (97)
Postmenopausal only after chemotherapy 47 (2) 53 (2) 100 (2)
Other 28 (1) 36 (1) 64 (1)
Tumor size
B2 cm 1,486 (62) 1,468 (61) 2,954 (62)
[2 cm 892 (37) 913 (38) 1,805 (38)
Unknown or missing 18 (\1) 21 (\1) 39 (\1)
Nodal status
Negative 1,383 (58) 1,406 (59) 2,789 (58)
1–3 positive nodes 714 (30) 700 (29) 1,414 (29)
C4 positive nodes 299 (12) 296 (12) 595 (12)
ER and PgR status
Positive/positive 1,485 (62) 1,464 (61) 2,949 (61)
Positive/negative or negative/positive 547 (23) 571 (24) 1,118 (23)
Other 364 (15) 367 (15) 731 (15)
Adjuvant or neoadjuvant chemotherapy
Yes 586 (24) 613 (26) 1,199 (25)
No 1,810 (76) 1,789 (74) 3,599 (75)
Tumor grade
I 594 (25) 644 (27) 1,238 (26)
II 1,146 (48) 1,118 (47) 2,264 (47)
III 295 (12) 307 (13) 602 (13)
Unknown or missing 361 (15) 333 (14) 694 (14)
Prior HRT use
No 1,562 (65) 1,517 (63) 3,079 (64)
Yes, within last 3 months 398 (17) 444 (18) 842 (18)
Yes, [3 months and \5 years ago 304 (13) 313 (13) 617 (13)
Yes, C5 years ago 132 (6) 127 (5) 259 (5)
Unknown or missing 0 (0) 1 (\1) 1 (\1)
Body mass index, kg/m2
\18.5 36 (2) 28 (1) 64 (1)
18.5–24.9 889 (37) 902 (38) 1,791 (37)
25–29.9 846 (35) 837 (35) 1,683 (35)
C30 535 (22) 544 (23) 1,079 (22)
Missing or unknown 90 (4) 91 (4) 181 (4)
Median (range)
Age, years 61 (38–88) 61 (39–84) 61 (38–88)
Weight, kg 68 (40–135) 68 (38–155) 68 (38–155)
Body mass index, kg/m2 26.0 (15.8–47.9) 26.1 (14.8–59.8) 26.1 (14.8–59.8)
Adjuvant chemotherapy 569 (24) 581 (24) 1,150 (24)
CMF 208 (9) 218 (9) 426 (9)
AC or EC 121 (5) 151 (6) 272 (6)
FEC 114 (5) 106 (4) 220 (5)
Taxane 8 (\ 1) 6 (\ 1) 14 (\ 1)
Other adjuvant chemotherapy 118 (5) 100 (4) 218 (5)
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Regression analysis was used to evaluate DFS and BCFI
following adjustment for baseline covariates. Proportional
hazards regression [19] stratified by randomization option
(2-arm vs. 4-arm) and chemotherapy use was used for DFS,
and the method of Fine and Gray [20] was used for BCFI.
Adjustment factors were treatment group, age quartile,
body mass index quartile, prior HRT use (yes or no), nodal
status (node-negative, 1–3 involved nodes, and C4 involved
nodes), tumor grade (I, II, III, and unknown), tumor size
(B2 cm, [2 cm, and unknown), and cooperative clinical
trial group. Indicator variables were included for the
occurrence of AMC symptoms, the occurrence of vaso-
motor symptoms, and the occurrence of both AMC and
vasomotor symptoms. Results were converted to hazard
ratios (along with 95 % confidence intervals and p-values)
relative to patients who experienced neither symptom.
Linear combinations of the regression-parameter estimates
were used to estimate hazard ratios corresponding to the
occurrence of vasomotor symptoms with or without AMC
symptoms, the occurrence of AMC symptoms with or
without vasomotor symptoms, and the occurrence of either
symptom. Coefficients for these linear combinations were
based on the proportions of patients in each adverse event
group in the regression model. We also investigated whe-
ther the association between adverse event occurrence and
outcome was modified by treatment assignment. This ana-
lysis consisted of adding treatment-by-adverse event inter-
action terms to the model. A wald test [21] was used to
determine whether any significant effect modification was
present. For all statistical tests, a two-sided p value less than
0.05 was considered statistically significant.
Results
Patient characteristics and incidence of treatment-
emergent adverse events
After exclusions, 4,798 patients were included in the
3-month analysis and 4,682 patients in the 12-month ana-
lysis (Fig. 1). Baseline characteristics were similar across
the two treatment groups as were the chemotherapies
received (Table 1). Almost 60 % of patients had node-
negative disease, and a minority of tumors were poorly
differentiated. Prior use of hormone replacement ther-
apy (HRT) was recorded in 36 % of the patients with 18 %
using HRT in the last 3 months before randomization. The
median age was 61 years, median BMI was 26, and median
weight 68 kg. The occurrence of AMC and/or vasomotor
symptoms was associated with treatment group, age quar-
tile, and prior HRT use in multivariable logistic regression
analysis (data not shown). Differences in the occurrence of
the adverse events according to treatment were, as expec-
ted, observed for vasomotor and AMC symptoms within 3
and 12 months of randomization (Table 2). The median
follow-up for this analysis was 7.0 years.
Duration of study treatment
Treatment discontinuation within 4.5 years for reasons
other than disease recurrence was higher for patients with
AMC symptoms compared with other groups. Considering
patients included in the 3-month landmark analysis, per-
cents (standard error) were 37.6 (4.4) and 38.4 (5.7) for the
group of patients reporting AMC symptoms alone and
those with both AMC and vasomotor symptoms, respec-
tively, compared with 18.2 (1.3) and 16.4 (0.6) for patients
with vasomotor alone and those with neither symptom
(p \ 0.0001, comparing all four groups). Similar results
were seen considering the 12-month landmark population.
Outcome—DFS and BCFI
Figure 2a, b shows the cumulative incidence of DFS events
over time for the four adverse event groups in the 3-month
analysis (Fig. 2a) and the 12-month analysis (Fig. 2b), both
showing a significant difference among the adverse event
groups (p = 0.001 and p \ 0.0001 for the 3- and 12-month
analyses, respectively). Results of the multivariable anal-
yses of DFS and BCFI are illustrated in Fig. 3. Table 3
shows adjusted DFS hazard ratios comparing each adverse
event group versus the group of patients experiencing
Table 1 continued
Letrozole (N = 2,396) Tamoxifen (N = 2,402) Total (N = 4,798)
number (%)
Neoadjuvant chemotherapy 51 (2) 65 (3) 116 (2)
Anthracycline based 27 (1) 40 (2) 67 (1)
Anthracycline/taxane based 13 (\ 1) 9 (\ 1) 22 (\ 1)
Other neoadjuvant chemotherapy 11 (\ 1) 16 (\ 1) 27 (\ 1)
CMF cyclophosphamide?methotrexate?5-fluorouracil, AC doxorubicin?cyclophosphamide, EC epirubicin?cyclophosphamide, FEC
5-fluorouracil?epirubicin?cyclophosphamide
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neither AMC symptoms nor vasomotor symptoms. DFS
was significantly better in patients with AMC symptoms
only (hazard ratio [HR] = 0.36, 95 % confidence interval
[CI] 0.18–0.73; HR = 0.57, 95 % CI 0.39–0.84 for the 3-
and 12-month analyses, respectively) and also in patients
experiencing AMC symptoms with or without vasomotor
symptoms (HR = 0.52, 95 % CI 0.32–0.86; HR = 0.65,
95 % CI 0.49–0.87 for the 3- and 12-month analyses,
respectively). By contrast, the occurrence of vasomotor
symptoms was less strongly associated with DFS, with a
significant association observed only in the 12-month
analysis in patients who experienced vasomotor symptoms
only (HR = 0.83, 95 % CI 0.70–0.97) and in patients who
experienced vasomotor symptoms with or without AMC
symptoms (HR = 0.82, 95 % CI 0.70–0.96).
Figure 2c, d illustrates BCFI, showing a significant
difference in the cumulative incidence of events over time
for the four adverse event groups in the 3-month (Fig. 2c)
and 12-month analysis (Fig. 2d), with p = 0.031 and
p = 0.023, respectively. Adjusted BCFI hazard ratios
comparing each adverse event group versus patients
experiencing neither AMC symptoms nor vasomotor
symptoms are shown in Table 4. BCFI was significantly
better in patients with AMC symptoms only (HR = 0.35,
95 % CI 0.14–0.86; HR = 0.57, 95 % CI 0.35–0.91 for
the 3- and 12-month analyses, respectively) and also in
patients experiencing AMC symptoms with or without
vasomotor symptoms (HR = 0.49, 95 % CI 0.26–0.92;
HR = 0.70, 95 % CI 0.49–0.99 for the 3- and 12-month
analyses, respectively). The occurrence of vasomotor
symptoms, either alone or in combination with AMC
symptoms, was not significantly associated with BCFI.
We found no significant interaction between treatment
group and adverse event occurrence when predicting DFS
(p for interaction = 0.24 and 0.73 for the 3- and
12-month analyses, respectively) or BCFI (p for interac-
tion = 0.34 and 0.71 for the 3- and 12-month analyses,
respectively).
Discussion
In our analysis of the monotherapy arms of BIG 1-98 trial,
patients reporting newly-occurring AMC symptoms at 3
and at 12 months follow-up had both significantly better
DFS and BCFI compared to those patients without these
reported side effects. This outcome was observed in both
tamoxifen-treated and letrozole-treated women, irrespec-
tive of whether AMC symptoms were reported alone or
together with vasomotor symptoms.
In contrast, for newly-reported vasomotor symptoms
without AMC symptoms, no significant difference in BCFI
was observed at either time point. Our findings were not
affected by treatment group, age, BMI, prior HRT use,
nodal status, tumor grade, tumor size, or cooperative
clinical trial group.
Table 2 Occurrence of adverse
events within 3 and 12 months
of randomization
a Percentages are based on the
total sample size of 4,798 (2,396
in the letrozole group and 2,402
in the tamoxifen group
b Percentages are based on the
4,682 patients who had no DFS
event within 12 months of
randomization (2,338 in the
letrozole group and 2,344 in the
tamoxifen group)
AMC arthralgia, myalgia, carpal
tunnel syndrome
Adverse event(s) Letrozole Tamoxifen Total P-value
Number (%)
Within 3 months of randomizationa
Neither side effect 1,843 (77) 1,826 (76) 3,669 (76) 0.47
Vasomotor symptoms (with or without
AMC symptoms)
459 (19) 545 (23) 1,004 (21) 0.0029
Vasomotor symptoms only 406 (17) 525 (22) 931 (19) \0.0001
AMC symptoms (with or without vasomotor
symptoms)
147 (6) 51 (2) 198 (4) \0.0001
AMC symptoms only 94 (4) 31 (1) 125 (3) \0.0001
Either side effect (but not both) 500 (21) 556 (23) 1,056 (22) 0.060
Both side effects 53 (2) 20 (\1) 73 (2) \0.0001
Within 12 months of randomizationb
Neither side effect 1,457 (62) 1,442 (62) 2,899 (62) 0.59
Vasomotor symptoms (with or without
AMC symptoms)
685 (29) 803 (34) 1,488 (32) 0.0003
Vasomotor symptoms only 543 (23) 732 (31) 1,275 (27) \0.0001
AMC symptoms (with or without
vasomotor symptoms)
338 (14) 170 (7) 508 (11) \0.0001
AMC symptoms only 196 (8) 99 (4) 295 (6) \0.0001
Either side effect (but not both) 739 (32) 831 (35) 1,570 (34) 0.0059
Both side effects 142 (6) 71 (3) 213 (5) \0.0001
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In our analysis, we included patients without a DFS
event during the first 3 months and without any known
vasomotor or AMC symptoms prior to treatment. We chose
to measure endocrine symptoms at 3 months follow-up to
exclude confounding factors such as non-adherence to
endocrine treatment or treatment discontinuation for other
reasons. Adherence to treatment within 3 months was good
in BIG 1-98, with only 159 patients never starting or
stopping treatment within the first 3 months. Since the
cumulative incidence of adverse events occurring in the
course of 12 months of treatment may better reflect the
individual response of the host to endocrine therapy, we
were also interested in results at the 12-month time point.
The increasing cumulative number of side effects after a
longer follow-up period may facilitate detecting differ-
ences between these groups; however, those patients suf-
fering from estrogen deprivation side effects—frequently
severe—may be more likely to discontinue treatment early
and thereby lose the benefit of DFS and BCFI risk
reduction.
Side effects and efficacy have been reported in other
large hormonal treatment trials for postmenopausal
women. The ATAC trial compared anastrozole to tamox-
ifen over 5 years in postmenopausal women with early
breast cancer. A retrospective analysis of the hormone
receptor-positive population of this trial showed that both
anastrozole- and tamoxifen-treated patients had a
significantly lower recurrence rates when new joint
symptoms and vasomotor symptoms of all grades were
reported after 3 months follow-up [22]. However, these
differences were only significant when joint symptoms
were considered with vasomotor symptoms. In patients
with vasomotor symptoms only, breast cancer recurrence
rates were not significantly lower compared to those
patients without occurrence of these symptoms (HR
0.84,95 %CI 0.68–1.03; p = 0.09). These results are sim-
ilar to ours, highlighting that the occurrence of joint
symptoms is primarily associated with an improved
outcome.
The TEAM trial compared 5 years of exemestane with
2.5–3 years of tamoxifen followed by 2–2.5 years of exe-
mestane [23]. A retrospective analysis of the German
cohort (1,502 women) investigating vasomotor and joint
symptoms of any grade occurring during the 5 year treat-
ment showed that arthralgia/myalgia and menopausal
symptoms during endocrine treatment were significantly
associated with longer OS and DFS than in those patients
not reporting these symptoms [24]; however, the effect on
OS was irrespective of study treatment given. A recent
report including the whole study population of the TEAM
trial showed a better outcome in terms of DFS and OS for
those with vasomotor-musculoskeletal and vulvovaginal
symptoms arising in the first year of endocrine treatment
compared to those not reporting these symptoms [25].
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Fig. 2 Cumulative incidence
according to occurrence of
adverse events within 3 months
(a, c) and within 12 months (b,
d) of randomization for disease-
free survival (DFS) (a, b) and
breast cancer-free interval
(BCFI) (c, d). Non-breast
cancer events are considered as
competing risks in the analysis
of BCFI. (AMC: arthralgia,
myalgia, carpal tunnel
syndrome)
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Disease-Free Survival−Adverse Events within 12 Months of Randomization
Variable
Hazard Ratio
(95% CI) P-Value
Hazard Ratio
0.25 0.5 0.75 1 1.5 2 3 4
Treatment group
Tamoxifen (referent) 1.00
Letrozole 0.80 (0.70–0.91)
Age quartile, yr
56 (referent) 1.00
57–61 1.22 (1.00–1.50)
62–67 1.19 (0.97–1.45)
68 1.76 (1.45–2.13)
Body mass index quartile
23.2 (referent) 1.00
23.3–26.1 0.90 (0.74–1.10)
26.2–29.6 0.92 (0.75–1.11)
29.7 0.93 (0.77–1.13)
Unknown/missing
Prior HRT use
No (referent) 1.00
Yes 0.83 (0.71–0.98)
Nodal status
Negative (referent) 1.00
1–3 positive nodes
4 positive nodes
Tumor grade
I (referent) 1.00
II 1.47 (1.22–1.77)
III 2.02 (1.60–2.54)
Unknown/missing
Tumor size
2 cm (referent) 1.00
>2 cm 1.50 (1.30–1.72)
Unknown/missing
Adverse event(s)
Neither (referent) 1.00
Vasomotor only
AMC only 0.57 (0.39–0.84)
Both side effects
0.0007
0.05
0.09
<0.0001
0.30
0.37
0.46
0.130.75 (0.52–1.08)
0.03
1.55 (1.32–1.82) <0.0001
2.96 (2.46–3.55) <0.0001
<0.0001
<0.0001
0.0011.45 (1.16–1.82)
<0.0001
0.111.67 (0.89–3.15)
0.02
0.004
0.21
0.83 (0.70–0.97)
0.78 (0.52–1.15)
Variable
Hazard Ratio
(95% CI) P-Value
Hazard Ratio
0.25 0.5 0.75 1 1.5 2 3 4
Treatment group
Tamoxifen (referent) 1.00
Letrozole 0.81 (0.72–0.92)
Age quartile, yr
56 (referent) 1.00
57–61 1.25 (1.03–1.51)
62–67 1.19 (0.99–1.44)
68 1.75 (1.46–2.10)
Body mass index quartile
23.2 (referent) 1.00
23.3–26.1 0.91 (0.76–1.10)
26.2–29.6 0.94 (0.78–1.12)
29.7 0.91 (0.76–1.10)
Unknown/missing
Prior HRT use
No (referent) 1.00
Yes 0.79 (0.67–0.92)
Nodal status
Negative (referent) 1.00
1–3 positive nodes
4 positive nodes
Tumor grade
I (referent) 1.00
II 1.45 (1.21–1.73)
III 2.09 (1.68–2.61)
Tumor size
2 cm (referent) 1.00
>2 cm 1.47 (1.29–1.68)
Adverse event(s)
Neither (referent) 1.00
Vasomotor only
AMC only 0.36 (0.18–0.73)
Both side effects
0.02
0.07
<0.0001
0.001
0.32
0.48
0.33
0.150.78 (0.55–1.10)
0.002
<0.0001
<0.0001
<0.0001
<0.0001
0.0002
<0.0001
0.20
0.07
0.005
0.890.96 (0.52–1.75)
0.85 (0.72–1.01)
1.51 (0.80–2.83)
1.48 (1.20–1.83)
2.89 (2.42–3.43)
1.55 (1.34–1.81)
Unknown/missing
Unknown/missing
Disease-Free Survival−Adverse Events within 3 Months of Randomization
 Breast-Cancer-Free Interval−Adverse Events within 3 Months of Randomization
Variable
Hazard Ratio
(95% CI) P-Value
Hazard Ratio
0.25 0.5 0.75 1 1.5 2 3 4 5
Treatment group
Tamoxifen (referent) 1.00
Letrozole 0.82 (0.70–0.96)
Age quartile, yr
56 (referent) 1.00
57–61 1.16 (0.93–1.44)
62–67 0.90 (0.71–1.13)
68 0.99 (0.80–1.24)
Body mass index quartile
23.2 (referent) 1.00
23.3–26.1 1.03 (0.82–1.29)
26.2–29.6 0.90 (0.71–1.13)
29.7 0.88 (0.70–1.11)
Unknown/missing
Prior HRT use
No (referent) 1.00
Yes 0.85 (0.70–1.02)
Nodal status
Negative (referent) 1.00
1–3 positive nodes
4 positive nodes
Tumor grade
I (referent) 1.00
II 1.71 (1.35–2.17)
III 2.90 (2.19–3.83)
Unknown/missing
Tumor size
2 cm (referent) 1.00
>2 cm 1.71 (1.44–2.02)
Unknown/missing
Adverse event(s)
Neither (referent) 1.00
Vasomotor only
AMC only 0.35 (0.14–0.86)
Both side effects
0.01
0.19
0.35
0.95
0.81
0.36
0.29
0.670.91 (0.60–1.39)
0.09
<0.0001
<0.0001
1.88 (1.55–2.28)
4.18 (3.40–5.14)
<0.0001
<0.0001
<0.00011.84 (1.40–2.42)
<0.0001
0.431.41 (0.61–3.25)
0.58
0.02
0.72
0.94 (0.77–1.16)
0.88 (0.44–1.78)
 Breast-Cancer-Free Interval−Adverse Events within 12 Months of Randomization
Variable
Hazard Ratio
(95% CI) P-Value
Hazard Ratio
0.25 0.5 0.75 1 1.5 2 3 4 5
Treatment group
Tamoxifen (referent) 1.00
Letrozole 0.79 (0.67–0.94)
Age quartile, yr
56 (referent) 1.00
57–61 1.12 (0.89–1.42)
62–67 0.88 (0.69–1.12)
68 0.97 (0.77–1.23)
Body mass index quartile
23.2 (referent) 1.00
23.3–26.1 1.09 (0.85–1.40)
26.2–29.6 0.96 (0.75–1.23)
29.7 0.91 (0.71–1.17)
Unknown/missing
Prior HRT use
No (referent) 1.00
Yes 0.89 (0.73–1.10)
Nodal status
Negative (referent) 1.00
1–3 positive nodes
4 positive nodes
Tumor grade
I (referent) 1.00
II 1.77 (1.37–2.28)
III 2.82 (2.10–3.80)
Unknown/missing
Tumor size
2 cm (referent) 1.00
>2 cm 1.77 (1.48–2.11)
Unknown/missing
Adverse event(s)
Neither (referent) 1.00
Vasomotor only
AMC only 0.57 (0.35–0.91)
Both side effects
0.006
0.33
0.28
0.83
0.48
0.74
0.47
0.760.93 (0.59–1.46)
0.28
<0.0001
<0.0001
1.83 (1.49–2.24)
4.25 (3.41–5.28)
<0.0001
<0.0001
<0.00011.81 (1.35–2.43)
<0.0001
0.301.57 (0.67–3.68)
0.82
0.02
0.78
0.98 (0.80–1.19)
0.94 (0.60–1.47)
(A) 
(C) (D) 
(B) 
Fig. 3 Multivariable analysis results according to occurrence of
adverse events within 3 months (a, c) and within 12 months (b, d) of
randomization for disease-free survival (DFS) based on proportional
hazards regression (a, b) and breast cancer-free interval (BCFI) based
on competing-risks regression (c, d). Hazard ratios are based on a
multivariable model including all variables listed as well as
cooperative trial group. Proportional hazards regression of DFS was
stratified by randomization option (2-arm vs. 4-arm) and chemother-
apy use. For each variable included, a hazard ratio less than 1.0
indicates lower hazard than the referent group, and a hazard ratio
greater than 1.0 indicates higher hazard than the referent group.
Hazard ratios are shown with 95 % CIs.
166 Breast Cancer Res Treat (2014) 143:159–169
123
Contrary to these results are emerging data from the
MA.27 trial—a study of 7,576 women with hormone
receptor-positive early breast cancer randomized to receive
5 years of endocrine treatment with anastrozole or exemes-
tane. The effect of early onset new or worsening vasomotor
or joint symptoms on relapse free survival was investigated.
At 3, 6, and 12 months, no significant improvement of RFS
could be observed regardless of whether or not there was a
prior history of vasomotor or joint symptoms [26, 27].
Similarly musculoskeletal symptoms at 6 months in a ret-
rospective analysis of the Intergroup Exemestane Study were
not associated with better outcome when adjusted for pos-
sible confounding factors [28].
Different baseline characteristics of patients as well as
differences in methodology to collect, categorize, analyze,
and report adverse events between these studies may con-
tribute to divergent findings. The adverse events of
tamoxifen were well-known when these trials were started,
whereas the less well-known adverse events of AIs were
not well-known and probably underreported, especially
early in the trials.
The exact mechanism involved in endocrine treatment
associated AMC symptoms remains unknown; however,
estrogen suppression is hypothesized to play an important
pathophysiological role. In our study, the percent of
women enrolled based on postmenopausal status follow-
ing chemotherapy was small and well-balanced across
both treatment arms. Recent data in a Korean population
suggest [29] that single nucleotide polymorphisms of
CYP19A1 are associated with both letrozole efficacy in
metastatic breast cancer and adverse events like arthral-
gia, myalgia, and hot flushes. Similar results were
observed in a Caucasian population where functional
polymorphisms in the CYP19A1 enzyme were associated
with the occurrence of arthralgia and myalgia [30].
A special subtype of CYP19A1 gene polymorphism was
found to be associated with both arthralgia/myalgia and
lower estrogen levels in postmenopausal women [30].
A report by Ingle et al. [31] identified 4 SNPs on chro-
mosome 14 that were associated with musculoskeletal
adverse events. Interestingly one of the SNPs created a
functional estrogen response element which influenced
the expression of TCL1A, the gene closest to the SNPs and
possibly associated with cytokine function. A recent study
reported that patients receiving tamoxifen and reporting
hot flushes were less likely to experience breast cancer
recurrence than those without these symptoms. It was
suggested that this may be due to greater conversion of
tamoxifen to its active metabolite endoxifen because of
polymorphisms in the cytochrom p450 complex [32].
However, analyses regarding CYP2D6 polymorphism in
the ATAC and BIG 1-98 populations do not support this
observation, since CYP2D6 phenotypes of reduced
enzyme activity were not associated with worse disease
control but, surprisingly, were associated with increased
incidence of vasomotor symptoms [33, 34].
Table 3 Disease-free survival
(DFS) according to occurrence
of adverse events
a Proportional hazards
regression stratified by
randomization option (2-arm vs.
4-arm) and chemotherapy use.
Hazard ratios are adjusted for
treatment group, age quartile,
body mass index quartile, prior
HRT use, nodal status, tumor
grade, tumor size, and
cooperative clinical trial group
AMC arthralgia, myalgia, or
carpal tunnel syndrome,
n number of DFS events, wy
woman years of follow-up, CI
confidence interval
Adverse event(s) n/wy (Annual
rate, %)
Hazard
ratioa
95 % CI p-value
Within 3 months of randomization
Neither side effect 820/20,137 (4.1) 1.00
Vasomotor symptoms (with or
without AMC symptoms)
192/5,477 (3.5) 0.86 0.73–1.02 0.084
Vasomotor symptoms only 181/5,106 (3.5) 0.85 0.72–1.01 0.073
AMC symptoms (with or without
vasomotor symptoms)
19/1,038 (1.8) 0.52 0.32–0.86 0.011
AMC symptoms only 8/666 (1.2) 0.36 0.18–0.73 0.0047
Either side effect 189/5,773 (3.3) 0.77 0.65–0.92 0.0043
Both side effects 11/371 (3.0) 0.96 0.52–1.75 0.89
Within 12 months of randomization
Neither side effect 633/14,221 (4.5) 1.00
Vasomotor symptoms (with or
without AMC symptoms)
253/7,107 (3.6) 0.82 0.70–0.96 0.014
Vasomotor symptoms only 226/6,160 (3.7) 0.83 0.70–0.97 0.023
AMC symptoms (with or without
vasomotor symptoms)
56/2,340 (2.4) 0.65 0.49–0.87 0.0031
AMC symptoms only 29/1,393 (2.1) 0.57 0.39–0.84 0.0039
Either side effect 255/7,553 (3.4) 0.77 0.66–0.90 0.0013
Both side effects 27/947 (2.9) 0.78 0.52–1.15 0.21
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Limitations of our study include the possible underre-
porting of AMC symptoms (at baseline and during follow-
up) because they were not collected with a pre-defined
checkbox. The incidence of arthralgia and myalgia in
particular at the 3 months time point (4.1 % of patients)
was low. It is possible that this under-reporting of symp-
toms influenced our results. The side effects reported in
randomized trials are frequently lower than seen in clinical
practice and patient reported toxicity may more compre-
hensively capture subjective side effects of therapies than
toxicity documented by trial investigators [35, 36]. Despite
these limitations, the hazard ratios of all endpoints were
consistently decreased both at 3 and at 12 months for both
end points for AMC symptoms.
Our data suggest that the occurrence of AMC symp-
toms at 3 and 12 months is associated with a significantly
better DFS and BCFI irrespective of treatment. Our
results are consistent with those in the ATAC and TEAM
trials. Based on these results, a prospective validation of
the influence of treatment-emergent symptoms and long-
term outcome with refined assessment of the side effects
is warranted. If confirmed, these results may improve
adherence to treatment despite these frequently bother-
some side effects.
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